论文部分内容阅读
从1975年开展,骨髓移植(BMT)疗法以来至今已有1000例,但对骨髓增生异常综合征(MDS)进行 BMT 的治疗是从1984年开始的,因此治疗例数还很少,故目前对治疗的把握性、适应标准进行探讨还不够充分。本文对 MDS的 BMT 的特征,结合作者的经验对日本和欧美的现状综述如下:一、MDS 的骨髓移植适应证对再生障碍性贫血和白血病的移植适应证,是根据年龄、病型、病期等而确定的,但对 MDS 的移植适应证至今尚未确立。1.年龄的适应在移植中年龄过大是最大的限制因素之一,MDS 同样是年轻患者的效果良好。在欧洲BMT 研究组(EBMTG)的报告中,对50岁以下
Since 1975, there have been 1000 cases of bone marrow transplantation (BMT) since, but the treatment of myelodysplastic syndrome (MDS) for BMT was started in 1984, so the treatment of cases is still very small, so the current The mastery of treatment, to adapt to the standard to explore is not sufficient. This article summarizes the characteristics of BMT in MDS and the author’s experience of Japan and Europe and the United States as follows: First, indications of bone marrow transplantation MDS indications for aplastic anemia and leukemia transplantation indications, is based on age, type, stage However, the indications of transplantation for MDS have not yet been established. 1. Adaptation of age Over-age in transplantation is one of the biggest limiting factors and MDS is also effective in younger patients. In the European BMT Study Group (EBMTG) report, under 50 years of age